Exploring the intersection of gender identity, hormone therapy, and reproductive possibilities
For transgender and gender diverse (TGD) individuals, gender-affirming hormone therapy (GAHT) can be a crucial step toward living authentically, bringing profound personal fulfillment. Yet, as these treatments help align physical characteristics with gender identity, they simultaneously raise important questions about future family planning. The very hormones that alleviate gender dysphoria by developing secondary sex characteristics also trigger significant changes in reproductive tissues and functions 1 .
More individuals are pursuing gender-affirming care during their reproductive years as societal awareness and acceptance of TGD identities expand 4 .
This creates a complex dilemma at the intersection of gender identity and reproductive science—how to balance immediate therapeutic needs with potential future parenthood goals. Recent systematic reviews have shed new light on both the biological impacts of GAHT on reproductive organs and the systemic barriers that limit fertility preservation access 1 2 .
Gender-affirming hormone therapy typically involves estrogen combined with testosterone-blocking medications for transfeminine people, and testosterone for transmasculine individuals . These treatments initiate physical changes that better align with a person's gender identity, but they also exert powerful effects on reproductive organs that can influence future fertility.
Estrogen and testosterone blockers can reduce sperm production and quality, making fertility preservation an important consideration before starting treatment.
Testosterone therapy may disrupt ovulation but doesn't always completely stop egg development, offering potential fertility options even after treatment begins.
| Aspect | Transfeminine Individuals | Transmasculine Individuals |
|---|---|---|
| Primary Hormones | Estrogen, Testosterone blockers | Testosterone |
| Impact on Gametes | Reduced sperm production & quality | Potential disruption of ovulation |
| Fertility Preservation | Sperm cryopreservation | Egg, embryo, or ovarian tissue freezing |
| Pregnancy Potential | Cannot carry pregnancy | May carry pregnancy if uterus preserved |
Major medical organizations including the World Professional Association for Transgender Health (WPATH), American Society for Reproductive Medicine (ASRM), and Endocrine Society now stress the importance of early, personalized counseling about fertility implications before starting GAHT 4 .
Recent systematic reviews have dramatically advanced our understanding of what actually happens to reproductive tissues under the influence of gender-affirming hormones. The 2024 systematic review published in Human Reproduction Update analyzed the cumulative findings from numerous studies, revealing both expected changes and surprising resilience in reproductive systems 1 .
Ovarian tissue shows significant histological changes, yet folliculogenesis persists during testosterone therapy 1 .
Testicular tissue undergoes dramatic changes including tubular atrophy and fibrosis 1 .
Despite structural alterations, most studies confirm that folliculogenesis persists even during testosterone therapy, challenging previous assumptions about complete ovarian shutdown 1 .
Testicular tissue shows tubular atrophy, hyalinization, and fibrosis with varying spermatogenic levels and increased rates of azoospermia 1 .
"The most hopeful finding concerns reversibility. For many TGD people, cessation of GAHT may allow restoration of some reproductive function, though the extent varies significantly."
While understanding GAHT's effects is crucial, equally important is examining the real-world outcomes of fertility preservation methods. Recent research has focused specifically on how these techniques perform for TGD individuals, with particular attention to both success rates and the unique challenges faced by this population.
| Preservation Method | Population | Key Findings | Considerations |
|---|---|---|---|
| Sperm Cryopreservation | Transfeminine | Successful even after GAHT initiation in some cases; better parameters with earlier preservation | Less expensive; at-home options available; masturbation may worsen dysphoria |
| Oocyte/Embryo Freezing | Transmasculine | Good success rates; possible without stopping testosterone in some protocols | Invasive procedure; may require stopping testosterone; higher cost |
| Ovarian Tissue Freezing | Transmasculine | Experimental option; offers alternative for those unable to undergo stimulation | Requires surgery; still considered experimental |
| Testicular Tissue Freezing | Transfeminine | Experimental; only option for prepubertal youth | Highly experimental; success rates unknown |
Transvaginal ultrasounds may worsen gender dysphoria for transmasculine individuals 3 6
Sperm collection through masturbation can be emotionally challenging for transfeminine individuals 6
Hormone fluctuations during egg stimulation may cause distress 3 6
These factors highlight why simply offering fertility preservation isn't enough—providers must implement trauma-informed approaches that actively minimize distress during these sensitive procedures.
The scientific advances in fertility preservation mean little if TGD people cannot access these services. A comprehensive 2025 systematic review in Reproductive Health journal identified several overlapping barriers that prevent TGD individuals from receiving adequate sexual and reproductive healthcare 2 .
Many providers lack training in TGD-competent care and fertility preservation options 2 .
Cis-normative healthcare environments create alienating experiences for TGD patients 2 .
| Barrier Category | Specific Challenges | Impact |
|---|---|---|
| Financial | High out-of-pocket costs; lack of insurance coverage | Limits access to fertility preservation services |
| Knowledge & Information | Inadequate provider training; insufficient patient counseling | Leads to uninformed decision-making |
| Systemic & Structural | Discriminatory policies; cis-normative healthcare environments | Creates exclusionary experiences |
| Psychological | Gender dysphoria triggered by procedures; decisional regret | Causes emotional distress during preservation process |
A 2024 study found that 77% of TGD participants had received some counseling about fertility preservation, but many described it as insufficient, with critical gaps in information about costs, location of services, and the actual effects of GAHT on fertility 4 .
As research in this field accelerates, several promising developments are reshaping the reproductive landscape for TGD people.
Testicular and ovarian tissue cryopreservation, originally developed for cancer patients, now offer potential options for those who cannot use standard preservation methods 3 .
The emergence of telehealth and at-home sperm preservation services specifically marketed to transgender women has begun addressing accessibility barriers for transfeminine individuals 6 .
Clinical practice is evolving toward more affirming approaches that acknowledge the full spectrum of gender diversity and minimize dysphoria during fertility procedures 3 .
Tracking outcomes before and after GAHT initiation to better isolate hormone effects 1 .
Investigating the reversibility of GAHT effects on reproduction, particularly for those who begin transition during youth 1 .
Following children born using gametes preserved after GAHT exposure to understand any long-term effects 1 .
"The goals for family-building and fertility preservation are diverse among the transgender community, and counseling should be tailored towards individuals' goals" 4 .
The journey toward understanding fertility in transgender and gender diverse individuals represents a powerful convergence of scientific inquiry and human compassion. While significant progress has been made in documenting the effects of gender-affirming hormones on reproductive organs, the most important lesson may be this: biological processes cannot be separated from the personal experiences of those navigating gender identity and family formation.
Building healthcare systems that honor the full humanity of TGD people requires addressing financial barriers, knowledge gaps, and systemic inequities.
The goal remains ensuring every person can pursue both gender congruence and family formation on their own terms.
The path forward requires continued research, certainly, but also a fundamental reimagining of reproductive healthcare as inherently inclusive—a system where gender diversity isn't accommodated as an afterthought but embraced as part of the beautiful spectrum of human experience.